Purpurogallin exerts anti-inflammatory effects in lipopolysaccharide- stimulated BV2 microglial cells through the inactivation of the NF-KB and MAPK signaling pathways

International Journal of Molecular Medicine

Volumn 32, Issue 5, 2013, Pages 1171-1178

  Park, Hye Young ^a   Kim, Tae Hoon ^b   Kim, Chan Gil ^c   Kim, Gi Young ^d   Kim, Cheol Min ^a,e   Kim, Nam Deuk ^a   Kim, Byung Woo ^a,f   Hwang, Hye Jin ^a,f   Choi, Yung Hyun ^f  

^a Pusan National University   (South Korea)

^b Daegu Haany University   (South Korea)

^c Konkuk University   (South Korea)

^d Jeju National University   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

^f Dong Eui University   (South Korea)

Author keywords

Anti inflammation; Mitogen activated protein kinase; Nuclear factor KB; Phosphatidylinositol 3 kinase Akt; Purpurogallin

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHENOL DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PURPUROGALLIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL VIABILITY; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; MICROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZOCYCLOHEPTENES; CELL LINE, TUMOR; HUMANS; LIPOPOLYSACCHARIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84885078824     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1478     Document Type: Article

References (50)

1. Mosley RL, Benner EJ, Kadiu I, Thomas M., Boska MD, Hasan K, Laurie C and Gendelman HE: Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin Neurosci Res 6: 261-281, 2006.
2. Reynolds A, Laurie C, Mosley RL and Gendelman HE: Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 82: 297-325, 2007.
3. Perry VH, Nicoll JA and Holmes C: Microglia in neurodegenerative disease. Nat Rev Neurol 6: 193-201, 2010.
4. Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immun 17: 13-19, 2003.
5. Das S and Basu A: Inflammation: a new candidate in modulating adult neurogenesis. J Neurosci Res 86: 1199-1208, 2008.
6. Stadelmann C: Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol 24 224-229, 2011.
7. Lull ME and Block ML: Microglial activation and chronic neurodegeneration. Neurotherapeutics 7: 354-365, 2010.
8. Long-Smith C.M., Sullivan AM and Nolan YM: The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 89: 277-287, 2009
9. Dixon RA and Steele CL Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci 4 394-400, 1999.
10. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR and Kolonel LN: Intake of flavonoids and lung cancer. J Natl Cancer Inst 92: 154-160, 2000.
11. Szejtli J and Szente L Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur J Pharm Biopharm 61: 115-125, 2005
12. Chen D, Chen MS, Cui Q.C., Yang H and Dou QP: Structure-proteasome- inhibitory activity relationships of dietary flavonoids in human cancer cells. Front Biosci 12: 1935-1945, 2007
13. Abou-Karam M and Shier WT: Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp nutgall. Phytother Res 13: 337-340, 1999
14. Wu TW, Zeng LH, Wu J, Fung K P, Weisel RD, Hempel A and Camerman N: Molecular structure and antioxidant specificity of purpurogallin in three types of human cardiovascular cells. Biochem Pharmacol 52: 1073-1080, 1996.
15. Prasad K and Laxdal VA: Evaluation of hydroxyl radical-scav-enging property of purpurogallin using high pressure liquid chromatography. Mol Cell Biochem 135: 153-158, 1994.
16. Sugiyama H, Fung KP and Wu TW: Purpurogallin as an anti-oxidant protector of human erythrocytes against lysis by peroxyl radicals. Life Sci 53: PL39-PL43, 1993.
17. Inamori Y, Muro C, Sajima E., Katagiri M, Okamoto Y, Tanaka H., Sakagami Y and Tsujibo H: Biological activity of purpurogallin. Biosci Biotechnol Biochem 61: 890-892, 1997.
18. Farnet CM, Wang B, Hansen M., Lipford JR, Zalkow L, Robinson WE Jr, Siegel J and Bushman F: Human immunodefi-ciency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother 42: 2245-2253, 1998.
19. Lambert JD, Chen D, Wang C.Y., Ai N., Sang S, Ho CT, Welsh WJ and Yang CS: Benzotropolone inhibitors of estradiol methylation: kinetics and in silico modeling studies. Bioorg Med Chem 13: 2501-2507, 2005.
20. Fung KP, Wu TW and Lui CP: Purpurogallin inhibits DNA synthesis of murine fibrosarcoma L-929 and human U-87 MG glioblastoma cells in vitro. Chemotherapy 42: 199-205, 1996.
21. Kitada S, Leone M, Sareth S., Zhai D, Reed JC and Pellecchia M: Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/ leukemia-2 proteins. J Med Chem 46: 4259-4264, 2003.
22. Tang G, Yang CY, Nikolovska-Coleska Z, Guo J., Qiu S, Wang R, Gao W., Wang G, Stuckey J, Krajewski K., Jiang S, Roller PP and Wang S: Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. J Med Chem 50: 1723-1726, 2007.
23. 2-induced DNA damage and apoptosis in cultured Jurkat cells. Free Radic Res 39: 125-135, 2005.
24. Méchin V., Baumberger S, Pollet B and Lapierre C: Peroxidase activity can dictate the in vitro lignin dehydrogenative polymer structure. Phytochemistry 68: 571-579, 2007.
25. Moniruzzaman M, Kamiya N and Goto M: Biocatalysis in water-in-ionic liquid microemulsions: a case study with horseradish peroxidase. Langmuir 25: 977-982, 2009.
26. Cheong MH, Lee SR, Yoo H.S., Jeong J W, Kim GY, Kim W.J., Jung IC and Choi YH: Anti-inflammatory effects of Polygala tenuifolia root through inhibition of NF-κB activation in lipo-polysaccharide-induced BV2 microglial cells. J Ethnopharmacol 137: 1402-1408, 2011.
27. Kim TH, Ku SK, Lee IC and Bae JS: Anti-inflammatory functions of purpurogallin in LPS-activated human endothelial cells. BMB Rep 45: 200-205, 2012.
28. Lee YA, Choi HM, Lee S.H., Yang HI, Yoo MC, Hong SJ and Kim KS: Synergy between adiponectin and interleukin-1β on the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in fibroblast-like synoviocytes. Exp Mol Med 44: 440-447, 2012.
29. Lee SH, Kim DW, Eom S.A., Jun SY, Park M, Kim DS, Kwon H.J., Kwon HY, Han KH, Park J, Hwang H.S., Eum WS and Choi SY: Suppression of 12-O- tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation in mice by transduced Tat-Annexin protein. BMB Rep 45: 354-359, 2012.
30. Atreya I, Atreya R and Neurath MF: NF-kappaB in inflammatory bowel disease. J Intern Med 263: 591-596, 2008.
31. Wright JG and Christman JW: The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2: 211-219, 2003.
32. Sebban H and Courtois G: NF-kappaB and inflammation in genetic disease. Biochem Pharmacol 72: 1153-1160, 2006.
33. Duyao MP, Buckler AJ and Sonenshein GE: Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci USA 87: 4727-4731, 1990.
34. Turjanski AG, Vaqué JP and Gutkind JS: MAP kinases and the control of nuclear events. Oncogene 26: 3240-3253, 2007.
35. Montagut C and Settleman J: Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134, 2009.
36. Garden GA and Möller T: Microglia biology in health and disease. J Neuroimmune Pharmacol 1: 127-137, 2006.
37. Sugama S, Takenouchi T, Fujita M., Conti B and Hashimoto M: Differential microglial activation between acute stress and lipo-polysaccharide treatment. J Neuroimmunol 207: 24-31, 2009.
38. Schwartz M and Shechter R: Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 6: 405-410, 2010.
39. Gebicke-Haerter PJ: Microglia in neurodegeneration: molecular aspects. Micros Res Tech 54: 47-58, 2001.
40. Inoue K: The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther 109: 210-226, 2006.
41. Merson TD, Binder MD and Kilpatrick TJ: Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. Neuromolecular Med 12: 99-132, 2 010.
42. Madrid LV, Wang CY, Guttridge D.C., Schottelius AJ, Baldwin AS Jr and Mayo MW: Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 20: 1626-1638, 2000.
43. Lee JY, Jhun BS, Oh Y.T., Lee JH, Choe W, Baik HH, Ha J, Yoon K.S., Kim SS and Kang I: Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett 396: 1-6, 2006.
44. Shin WS, Szuba A and Rockson SG: The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160: 91-102, 2002.
45. Nam NH: Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6: 945-951, 2006.
46. Luqman S and Pezzuto JM: NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res 24: 949-963, 2010.
47. Kaminska B: MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754: 253-262, 2005.
48. Kaminska B, Gozdz A, Zawadzka M., Ellert-Miklaszewska A and Lipko M: MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec (Hoboken) 292: 1902-1913, 2009.
49. Wei J and Feng J: Signaling pathways associated with inflam-matory bowel disease. Recent Pat Inflamm Allergy Drug Discov 4: 105-117, 2010.
50. Pyo H, Jou I, Jung S., Hong S and Joe EH: Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport 9: 871-874, 1998.